[
Humans
Positron-Emission Tomography
/ methods
Male
Adult
Female
Up-Regulation
/ physiology
ATP Binding Cassette Transporter, Subfamily B, Member 1
/ metabolism
Middle Aged
Young Adult
Metoclopramide
Epilepsy, Temporal Lobe
/ metabolism
Carbon Radioisotopes
/ pharmacokinetics
Drug Resistant Epilepsy
/ metabolism
Brain
/ metabolism
Seizures
/ metabolism
Magnetic Resonance Imaging
/ methods
Blood-Brain Barrier
/ metabolism
Blood-brain barrier
Drug-resistant epilepsy
P-glycoprotein
PET
[11C]Metoclopramide
Journal
Fluids and barriers of the CNS
ISSN: 2045-8118
Titre abrégé: Fluids Barriers CNS
Pays: England
ID NLM: 101553157
Informations de publication
Date de publication:
28 Oct 2024
28 Oct 2024
Historique:
received:
19
08
2024
accepted:
21
10
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
epublish
Résumé
P-glycoprotein (P-gp) is an efflux transporter which is abundantly expressed at the blood-brain barrier (BBB) and which has been implicated in the pathophysiology of various brain diseases. The radiolabelled antiemetic drug [ Eight patients with drug-resistant (DRE) TLE, 5 seizure-free patients with drug-sensitive (DSE) focal epilepsy, and 15 healthy subjects underwent brain PET imaging with [ DRE patients but not DSE patients showed significantly higher k [ EudraCT 2019-003137-42. Registered 28 February 2020.
Sections du résumé
BACKGROUND
BACKGROUND
P-glycoprotein (P-gp) is an efflux transporter which is abundantly expressed at the blood-brain barrier (BBB) and which has been implicated in the pathophysiology of various brain diseases. The radiolabelled antiemetic drug [
METHODS
METHODS
Eight patients with drug-resistant (DRE) TLE, 5 seizure-free patients with drug-sensitive (DSE) focal epilepsy, and 15 healthy subjects underwent brain PET imaging with [
RESULTS
RESULTS
DRE patients but not DSE patients showed significantly higher k
CONCLUSIONS
CONCLUSIONS
[
TRIAL REGISTRATION
BACKGROUND
EudraCT 2019-003137-42. Registered 28 February 2020.
Identifiants
pubmed: 39465417
doi: 10.1186/s12987-024-00588-8
pii: 10.1186/s12987-024-00588-8
doi:
Substances chimiques
ATP Binding Cassette Transporter, Subfamily B, Member 1
0
Metoclopramide
L4YEB44I46
Carbon Radioisotopes
0
Carbon-11
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
87Subventions
Organisme : Austrian Science Fund
ID : I4470-B
Organisme : Austrian Science Fund
ID : I4470-B
Organisme : Austrian Science Fund
ID : I4470-B
Organisme : Austrian Science Fund
ID : I4470-B
Organisme : Agence nationale de la recherche
ID : ANR-19-CE17-0027
Organisme : Agence nationale de la recherche
ID : ANR-19-CE17-0027
Informations de copyright
© 2024. The Author(s).
Références
Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A. 1989;86:695–8. https://doi.org/10.1073/pnas.86.2.695
doi: 10.1073/pnas.86.2.695
pubmed: 2563168
pmcid: 286540
Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest. 2005;115:3285–90. https://doi.org/10.1172/JCI25247
doi: 10.1172/JCI25247
pubmed: 16239972
pmcid: 1257538
Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77:491–502.
doi: 10.1016/0092-8674(94)90212-7
pubmed: 7910522
Baltira C, Aronica E, Elmquist WF, Langer O, Löscher W, Sarkaria JN, et al. The impact of ATP-binding cassette transporters in the diseased brain: context matters. Cell Rep Med. 2024;5:101609. https://doi.org/10.1016/j.xcrm.2024.101609
doi: 10.1016/j.xcrm.2024.101609
pubmed: 38897176
pmcid: 11228798
Bauer M, Tournier N, Langer O. Imaging P-glycoprotein function at the blood-brain barrier as a determinant of the variability in response to central nervous system drugs. Clin Pharmacol Ther. 2019;105:1061–4. https://doi.org/10.1002/cpt.1402
doi: 10.1002/cpt.1402
pubmed: 30903694
pmcid: 6491962
Pottier G, Marie S, Goutal S, Auvity S, Peyronneau MA, Stute S, et al. Imaging the impact of the P-glycoprotein (ABCB1) function on the brain kinetics of metoclopramide. J Nucl Med. 2016;57:309–14. https://doi.org/10.2967/jnumed.115.164350
doi: 10.2967/jnumed.115.164350
pubmed: 26585058
Savolainen H, Windhorst AD, Elsinga PH, Cantore M, Colabufo NA, Willemsen AT, et al. Evaluation of [
doi: 10.1177/0271678X16654493
pubmed: 27354093
Auvity S, Caillé F, Marie S, Wimberley C, Bauer M, Langer O, et al. P-glycoprotein (ABCB1) inhibits the influx and increases the efflux of
doi: 10.2967/jnumed.118.210104
pubmed: 29748235
Mairinger S, Leterrier S, Filip T, Lobsch M, Pahnke J, Hernandez-Lozano I, et al. [
doi: 10.1177/0271678X231202336
pubmed: 37728771
Tournier N, Bauer M, Pichler V, Nics L, Klebermass EM, Bamminger K, et al. Impact of P-glycoprotein function on the brain kinetics of the weak substrate
doi: 10.2967/jnumed.118.219972
pubmed: 30630940
pmcid: 6604692
Zoufal V, Mairinger S, Brackhan M, Krohn M, Filip T, Sauberer M, et al. Imaging P-glycoprotein induction at the blood-brain barrier of a beta-amyloidosis mouse model with
doi: 10.2967/jnumed.119.237198
pubmed: 31806767
pmcid: 7383073
Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia. 1995;36:1–6. https://doi.org/10.1111/j.1528-1157.1995.tb01657.x
doi: 10.1111/j.1528-1157.1995.tb01657.x
pubmed: 8001500
Liu JY, Thom M, Catarino CB, Martinian L, Figarella-Branger D, Bartolomei F, et al. Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy. Brain. 2012;135:3115–33. https://doi.org/10.1093/brain/aws147
doi: 10.1093/brain/aws147
pubmed: 22750659
Aronica E, Gorter JA, Ramkema M, Redeker S, Ozbas-Gerceker F, van Vliet EA, et al. Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia. 2004;45:441–51. https://doi.org/10.1111/j.0013-9580.2004.57703.x
doi: 10.1111/j.0013-9580.2004.57703.x
pubmed: 15101825
Bauer B, Hartz AM, Pekcec A, Toellner K, Miller DS, Potschka H. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol. 2008;73:1444–53. https://doi.org/10.1124/mol.107.041210
doi: 10.1124/mol.107.041210
pubmed: 18094072
Tang F, Hartz AMS, Bauer B. Drug-resistant epilepsy: multiple hypotheses, few answers. Front Neurol. 2017;8:301. https://doi.org/10.3389/fneur.2017.00301
doi: 10.3389/fneur.2017.00301
pubmed: 28729850
pmcid: 5498483
Löscher W. Epilepsy and alterations of the blood-brain barrier: cause or consequence of epileptic seizures or both? Handb Exp Pharmacol. 2022;273:331–50. https://doi.org/10.1007/164_2020_406
doi: 10.1007/164_2020_406
pubmed: 33136189
Traub-Weidinger T, Muzik O, Sundar LKS, Aull-Watschinger S, Beyer T, Hacker M, et al. Utility of absolute quantification in non-lesional extratemporal lobe epilepsy using FDG PET/MR imaging. Front Neurol. 2020;11:54. https://doi.org/10.3389/fneur.2020.00054
doi: 10.3389/fneur.2020.00054
pubmed: 32082251
pmcid: 7005011
Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 2010;51:1069–77. https://doi.org/10.1111/j.1528-1167.2009.02397.x
doi: 10.1111/j.1528-1167.2009.02397.x
pubmed: 19889013
Zhang C, Kwan P, Zuo Z, Baum L. The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev. 2012;64:930–42. https://doi.org/10.1016/j.addr.2011.12.003
doi: 10.1016/j.addr.2011.12.003
pubmed: 22197850
Pichler V, Ozenil M, Bamminger K, Vraka C, Hacker M, Langer O, et al. Pitfalls and solutions of the fully-automated radiosynthesis of [
doi: 10.1186/s41181-019-0083-2
pubmed: 31853677
pmcid: 6920278
Shin JW, Chu K, Shin SA, Jung KH, Lee ST, Lee YS, et al. Clinical applications of simultaneous PET/MR imaging using (R)-[
doi: 10.3174/ajnr.A4566
pubmed: 26585254
pmcid: 7960172
Feldmann M, Asselin MC, Liu J, Wang S, McMahon A, Anton-Rodriguez J, et al. P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. Lancet Neurol. 2013;12:777–85. https://doi.org/10.1016/S1474-4422(13)70109-1
doi: 10.1016/S1474-4422(13)70109-1
pubmed: 23786896
Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19:224–47. https://doi.org/10.1002/hbm.10123
doi: 10.1002/hbm.10123
pubmed: 12874777
pmcid: 6871794
Wagner CC, Bauer M, Karch R, Feurstein T, Kopp S, Chiba P, et al. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-
doi: 10.2967/jnumed.109.063289
pubmed: 19910428
Kreisl WC, Liow JS, Kimura N, Seneca N, Zoghbi SS, Morse CL, et al. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer
doi: 10.2967/jnumed.109.070151
pubmed: 20237038
Mossel P, Arif WM, De Souza GS, Varela LG, van der Weijden CWJ, Boersma HH, et al. Quantification of P-glycoprotein function at the human blood-brain barrier using [
doi: 10.1007/s00259-023-06363-5
pubmed: 37552369
pmcid: 10611838
Bankstahl JP, Bankstahl M, Kuntner C, Stanek J, Wanek T, Meier M, et al. A novel PET imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier. J Neurosci. 2011;31:8803–11. https://doi.org/10.1523/JNEUROSCI.6616-10.2011
doi: 10.1523/JNEUROSCI.6616-10.2011
pubmed: 21677164
pmcid: 3693085
Luurtsema G, Molthoff CF, Schuit RC, Windhorst AD, Lammertsma AA, Franssen EJ. Evaluation of (R)-[
doi: 10.1016/j.nucmedbio.2004.06.007
pubmed: 15691665
Abrahim A, Luurtsema G, Bauer M, Karch R, Lubberink M, Pataraia E, et al. Peripheral metabolism of (R)-[
doi: 10.1007/s00259-007-0556-5
pubmed: 17846766
Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos. 2005;33:165–74. https://doi.org/10.1124/dmd.104.001230
doi: 10.1124/dmd.104.001230
pubmed: 15502009
Desta Z, Wu GM, Morocho AM, Flockhart DA. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos. 2002;30:336–43. https://doi.org/10.1124/dmd.30.3.336
doi: 10.1124/dmd.30.3.336
pubmed: 11854155
Breuil L, Ziani N, Leterrier S, Hugon G, Caille F, Bouilleret V, et al. Impact of cytochrome induction or inhibition on the plasma and brain kinetics of [
El Biali M, Wölfl-Duchek M, Jackwerth M, Mairinger S, Weber M, Bamminger K, et al. St. John’s wort extract with a high hyperforin content does not induce P-glycoprotein activity at the human blood-brain barrier. Clin Transl Sci. 2024;17:e13804. https://doi.org/10.1111/cts.13804
doi: 10.1111/cts.13804
pubmed: 38700454
pmcid: 11067874
Bauer M, Bamminger K, Pichler V, Weber M, Binder S, Maier-Salamon A, et al. Impaired clearance from the brain increases the brain exposure to metoclopramide in elderly subjects. Clin Pharmacol Ther. 2021;109:754–61. https://doi.org/10.1002/cpt.2052
doi: 10.1002/cpt.2052
pubmed: 32966590
Breuil L, El Biali M, Vodovar D, Marie S, Auvity S, Bauer M, et al. Parametric imaging of P-glycoprotein function at the blood-brain barrier using k
doi: 10.1007/s11307-023-01864-z
pubmed: 37801196